Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Why is gout so poorly managed?

Literature DB >> 17881662

Why is gout so poorly managed?

Eliseo Pascual, Francisca Sivera.

Abstract

Entities: Disease

Mesh：

Substances：
Uric Acid

Year: 2007 PMID： 17881662 PMCID： PMC1994299 DOI： 10.1136/ard.2007.078469

Source DB: PubMed Journal: Ann Rheum Dis ISSN： 0003-4967 Impact factor: 19.103

× No keyword cloud information.

36 in total

1. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout.

Authors: Eliseo Pascual; Francisca Sivera
Journal: Ann Rheum Dis Date: 2007-01-12 Impact factor: 19.103

2. First metatarsophalangeal joint aspiration using a 29-gauge needle.

Authors: F Sivera; R Aragon; E Pascual
Journal: Ann Rheum Dis Date: 2007-06-08 Impact factor: 19.103

Review 3. Therapeutic advances in gout.

Authors: Eliseo Pascual; Francisca Sivera
Journal: Curr Opin Rheumatol Date: 2007-03 Impact factor: 5.006

4. A survey of current evaluation and treatment of gout.

Authors: Naomi Schlesinger; Dirk F Moore; Jennifer D Sun; H Ralph Schumacher
Journal: J Rheumatol Date: 2006-10 Impact factor: 4.666

5. The management of gout at an academic healthcare center in Beijing: a physician survey.

Authors: Weigang Fang; Xuejun Zeng; Mengtao Li; Lan X Chen; H Ralph Schumacher; Fengchun Zhang
Journal: J Rheumatol Date: 2006-10 Impact factor: 4.666

6. Gout medication treatment patterns and adherence to standards of care from a managed care perspective.

Authors: Chaitanya A Sarawate; Kathleen K Brewer; Wenya Yang; Pankaj A Patel; H Ralph Schumacher; Kenneth G Saag; Alan W Bakst
Journal: Mayo Clin Proc Date: 2006-07 Impact factor: 7.616

7. Withdrawal of longterm antihyperuricemic therapy in tophaceous gout.

Authors: M F van Lieshout-Zuidema; F C Breedveld
Journal: J Rheumatol Date: 1993-08 Impact factor: 4.666

Review 8. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Authors: W Zhang; M Doherty; E Pascual; T Bardin; V Barskova; P Conaghan; J Gerster; J Jacobs; B Leeb; F Lioté; G McCarthy; P Netter; G Nuki; F Perez-Ruiz; A Pignone; J Pimentão; L Punzi; E Roddy; T Uhlig; I Zimmermann-Gòrska
Journal: Ann Rheum Dis Date: 2006-05-17 Impact factor: 19.103

Review 9. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Authors: W Zhang; M Doherty; T Bardin; E Pascual; V Barskova; P Conaghan; J Gerster; J Jacobs; B Leeb; F Lioté; G McCarthy; P Netter; G Nuki; F Perez-Ruiz; A Pignone; J Pimentão; L Punzi; E Roddy; T Uhlig; I Zimmermann-Gòrska
Journal: Ann Rheum Dis Date: 2006-05-17 Impact factor: 19.103

10. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations.

Authors: Edward Roddy; Weiya Zhang; Michael Doherty
Journal: Ann Rheum Dis Date: 2007-05-15 Impact factor: 19.103

26 in total

Review 1. International position paper on febuxostat.

Authors: Tim L Jansen; Pascal Richette; Fernando Perez-Ruiz; Anne-Kathrin Tausche; Philip-André Guerne; Leonardo Punzi; Burkhard Leeb; Victoria Barskova; Till Uhlig; José Pimentão; Irena Zimmermann-Górska; Elisio Pascual; Thomas Bardin; Michael Doherty
Journal: Clin Rheumatol Date: 2010-04-17 Impact factor: 2.980

2. Quality of care in patients with gout: why is management suboptimal and what can be done about it?

Authors: N Lawrence Edwards
Journal: Curr Rheumatol Rep Date: 2011-04 Impact factor: 4.592

3. A Pharmacist-Staffed, Virtual Gout Management Clinic for Achieving Target Serum Uric Acid Levels: A Randomized Clinical Trial.

Authors: Robert Goldfien; Alice Pressman; Alice Jacobson; Michele Ng; Andrew Avins
Journal: Perm J Date: 2016-07-01

Why is gout so poorly managed?

1. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout.

2. First metatarsophalangeal joint aspiration using a 29-gauge needle.

Review 3. Therapeutic advances in gout.

4. A survey of current evaluation and treatment of gout.

5. The management of gout at an academic healthcare center in Beijing: a physician survey.

6. Gout medication treatment patterns and adherence to standards of care from a managed care perspective.

7. Withdrawal of longterm antihyperuricemic therapy in tophaceous gout.

Review 8. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Review 9. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

10. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations.

Review 1. International position paper on febuxostat.

2. Quality of care in patients with gout: why is management suboptimal and what can be done about it?

3. A Pharmacist-Staffed, Virtual Gout Management Clinic for Achieving Target Serum Uric Acid Levels: A Randomized Clinical Trial.

4. [Diagnosis and management of gout in Austria. Survey of current practice considering the EULAR recommendations].

Review 5. Imaging in gout: A review of the recent developments.

Review 6. Managing Gout in the Patient with Renal Impairment.

Review 7. Management of gout in general practice--a systematic review.

Review 8. Management of hyperuricemia in gout: focus on febuxostat.

9. New advances in the treatment of gout: review of pegloticase.

Review 10. Gout: optimizing treatment to achieve a disease cure.